Delivery Order HHSN272201600005I-75N93022F00001
Award Date 7/20/22
Potential Completion Date 8/18/23
Potential Value $1.2M
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Frederick, MD 21702, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This contract award was issued by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $136,259.00 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 contract, which funds a Phase 1 clinical trial unit for therapeutics against infectious diseases. The contract type is cost plus fixed fee, and there is no...
- The National Institute of Allergy and Infectious Diseases awarded Task Order 75N93022F00001 to Dynport Vaccine Company LLC, a General Dynamics subsidiary, on January 21, 2022, with a ceiling value of $2.19 million and a completion date of January 13, 2032. This delivery order operates under the Early Phase Clinical Trial Units IDIQ, a $346 million multiple-award vehicle designed to support Phase I clinical trial services for infectious disease candidates. The contract employs a...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $129,318.29 contract is a cost-plus-fixed-fee delivery order under the "Therapeutics Against Infectious Diseases Phase 1" contract vehicle, which funds Phase 1 clinical trials for infectious disease therapeutics. Dynport will provide a range of services including preclinical development,...
- This is a $1,159,290,240.64 cost-plus-award-fee contract awarded by the Department of the Army Medical Command to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The contract, which has no set-aside designation, is for research, development, manufacturing, and testing services to support biopharmaceutical products targeting infectious diseases. Dynport has provided similar services under past federal contracts with NIH, HHS, and the Joint Program Executive Office for...
- This is a $2,265,501.00 delivery order contract awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Early Phase Clinical Trial Units (EPCTU) IDIQ contract vehicle. The contract is for cost plus fixed fee services to support early phase clinical trials, with a period of performance through July 15, 2025. The contract does not have a set-aside designation. Dynport Vaccine Company has...
- This delivery order, awarded on May 13, 2021, to Dynport Vaccine Company LLC (a General Dynamics subsidiary) by the National Institute of Allergy and Infectious Diseases (NIAID), provides $4.12 million under a cost-plus-fixed-fee structure to establish a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The work is being performed in Frederick, Maryland, with an ultimate completion date of January 31, 2025. This delivery order is issued under the $346 million Early...
- The Joint Program Executive Office for Chemical and Biological Defense awarded a $29.1 million firm fixed price definitive contract to Dynport Vaccine Company LLC on August 6, 2021, for vaccine stability testing services. The contract extends through December 15, 2027, and is performed at Dynport's Frederick, Maryland facility. Dynport, a General Dynamics subsidiary specializing in biopharmaceutical research, development, manufacturing, and testing services for infectious disease therapeutics...
- This is a $3,026,999.00 firm fixed price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for the development of a recombinant Type E botulinum neurotoxin vaccine. The contract has a completion date of September 29, 2006 and does not use a set-aside designation. Dynport Vaccine Company LLC is a limited liability company that provides research, development,...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Dynport Vaccine Company LLC on December 14, 2018, under the Therapeutics Against Infectious Diseases Phase 1 IDIQ, with a ceiling value of $99,978.65 for Phase 1 clinical trial unit operations. Place of performance is Frederick, Maryland. The order was funded under Cost Plus Fixed Fee pricing with ultimate completion on December 14, 2019. The work supports a Phase 1 clinical trial unit for therapeutics against...
- This is a $235,119,970.93 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The contract is for pandemic influenza preparedness and includes services such as preclinical development, clinical trials, diagnostic testing, vaccine stability evaluations, and cGMP production. The contract is not set aside and is a definitive contract rather than an indefinite delivery vehicle...